Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Recent Patents on Anti-Cancer Drug Discovery
|
December 4, 2009
Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer
Anne Kendall, Rosemary Lord, Nick Maisey
Frontiers in Pharmacology
|
July 20, 2023
<i>CYP3A</i> genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
Laurence McEvoy, Joanne Cliff, Daniel F Carr, et al.
Endocrine Connections
|
March 13, 2020
Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction
Anna Olsson-Brown, Rosemary Lord, Joseph Sacco, et al.
Frontiers in Pharmacology
|
September 18, 2023
Corrigendum: <i>CYP3A</i> genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
Laurence McEvoy, Joanne Cliff, Daniel F Carr, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 24, 2020
Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors
Rosemary Lord, Jyoti Rauniyar, Tamsin Morris, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 17, 2024
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)
Agnieszka Michael, William Wilson, Sunny Sunshine, et al.
The Lancet. Oncology
|
October 18, 2015
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
R Paul Symonds, Charlie Gourley, Susan Davidson, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
August 3, 2024
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene
Robert D Morgan, George J Burghel, Nicola Flaum, et al.
Gynecologic Oncology
|
May 28, 2019
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903
Linda Mileshkin, Richard Edmondson, Rachel L O'Connell, et al.
Cancer Research Communications
|
March 27, 2023
<i>Ad hoc</i> Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline <i>BRCA</i> Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects
Mansoor Raza Mirza, Gabriel Lindahl, Sven Mahner, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Recent Patents on Anti-Cancer Drug Discovery
|
December 4, 2009
Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer
Anne Kendall, Rosemary Lord, Nick Maisey
Frontiers in Pharmacology
|
July 20, 2023
<i>CYP3A</i> genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
Laurence McEvoy, Joanne Cliff, Daniel F Carr, et al.
Endocrine Connections
|
March 13, 2020
Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction
Anna Olsson-Brown, Rosemary Lord, Joseph Sacco, et al.
Frontiers in Pharmacology
|
September 18, 2023
Corrigendum: <i>CYP3A</i> genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
Laurence McEvoy, Joanne Cliff, Daniel F Carr, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 24, 2020
Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors
Rosemary Lord, Jyoti Rauniyar, Tamsin Morris, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 17, 2024
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)
Agnieszka Michael, William Wilson, Sunny Sunshine, et al.
The Lancet. Oncology
|
October 18, 2015
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
R Paul Symonds, Charlie Gourley, Susan Davidson, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
August 3, 2024
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene
Robert D Morgan, George J Burghel, Nicola Flaum, et al.
Gynecologic Oncology
|
May 28, 2019
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903
Linda Mileshkin, Richard Edmondson, Rachel L O'Connell, et al.
Cancer Research Communications
|
March 27, 2023
<i>Ad hoc</i> Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline <i>BRCA</i> Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects
Mansoor Raza Mirza, Gabriel Lindahl, Sven Mahner, et al.
Page
of 2